Seelos Therapeutics: Year-End Results and Business Highlights Microdose – Microdose Psychedelic Insights

Even if not on most peoples sexiest shroom stock list, Seelos Therapeuticshas been a solid presence in the psychedelic medicine space for some time.

For those who might not know, Seelos is a biopharmaceutical company focused on the development of novel therapeutics to treat central nervous system (CNS) disorders and other rare conditions.

The company has a portfolio of non-psychedelic compounds but its their SLS-002, an intranasal ketamine, thats made them an often overlooked but serious psychedelic player.

In 2019, the FDA granted Fast Track designation for Seelos SLS-002 molecule (ketamine) and Seelos has begun dosing patients as part of a study for Major Depressive Disorder giving the company a leg-up in the approval process of psychedelics.

With $20 million in capital raised in November, Seelos now has $78.7mm in cash on hand, a very healthy number that can help them withstand the current market pullback.

Theyre also in advanced clinical trials for other compounds like SLS-005, which is moving forward to Phase IIb/III after approval of its IND application by the FDA.

A pretty solid pipeline. See below for the companys 2021 year-end results and business highlights.

NEWS PROVIDED BY

Seelos Therapeutics, Inc.

Mar 07, 2022, 08:00 ET

NEW YORK, March 7, 2022 /PRNewswire/ Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced its year-end 2021 business and clinical update.

In the second half of 2021, we continued to accomplish several significant milestones and continued to execute in the face of one of the most difficult environments for publicly-traded biotech companies that Ive seen in my career, said Raj Mehra Ph.D., Chairman and CEO of Seelos. We began the placebo-controlled Part 2 of the registration directed study of SLS-002 and plan to enroll in over 30 sites. The SLS-005 IV trehalose programs registrational study in ALS, which was accepted into the HEALEY ALS Platform Trial at Harvard, commenced dosing participants in February 2022 and our IND was accepted to study SLS-005 in spinocerebellar ataxia and its Phase IIb/III pivotal study should begin dosing in Q2 2022. We have begun additional in vivo studies with our Parkinsons disease focused gene therapy program SLS-004 after demonstrating its capability of reducing alpha-synuclein expression. We look forward to continuing to provide meaningful updates on the current state of progress on all of our programs as well as additional initiatives.

Seelos Clinical Update

SLS-002 (intranasal racemic ketamine)

SLS-005 (IV Trehalose)

SLS-004 and SLS-007 (Parkinsons disease gene therapy programs)

Seelos Business Update

Contact Information:

Anthony Marciano

Head of Corporate Communications

Seelos Therapeutics, Inc. (Nasdaq: SEEL)

300 Park Avenue, 2ndFloor

New York, NY 10022

(646) 293-2136

anthony.marciano@seelostx.com

https://seelostherapeutics.com/

Tweets by seelostx

https://www.linkedin.com/company/seelos

Mike Moyer

Managing Director

LifeSci Advisors, LLC

250 West 55th St., Suite 3401

New York, NY 10019

(617) 308-4306

mmoyer@lifesciadvisors.com

SOURCE Seelos Therapeutics, Inc.

Read the original here:

Seelos Therapeutics: Year-End Results and Business Highlights Microdose - Microdose Psychedelic Insights